IN2015DN02829A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02829A IN2015DN02829A IN2829DEN2015A IN2015DN02829A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A IN 2829DEN2015 A IN2829DEN2015 A IN 2829DEN2015A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011001692 | 2011-10-10 | ||
| PCT/EP2012/069936 WO2013053690A1 (en) | 2011-10-10 | 2012-10-09 | Pde9i with imidazo pyrazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02829A true IN2015DN02829A (instruction) | 2015-09-11 |
Family
ID=47019007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2829DEN2015 IN2015DN02829A (instruction) | 2011-10-10 | 2012-10-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9643970B2 (instruction) |
| EP (2) | EP2906562B1 (instruction) |
| JP (1) | JP2015531401A (instruction) |
| CN (2) | CN104703987B (instruction) |
| AU (2) | AU2012323085B2 (instruction) |
| BR (1) | BR112015007731B1 (instruction) |
| CA (1) | CA2886885C (instruction) |
| HK (1) | HK1211023A1 (instruction) |
| IL (2) | IL237836A (instruction) |
| IN (1) | IN2015DN02829A (instruction) |
| MA (1) | MA37958B1 (instruction) |
| MX (2) | MX381326B (instruction) |
| SG (1) | SG11201502728WA (instruction) |
| TN (1) | TN2015000100A1 (instruction) |
| WO (1) | WO2013053690A1 (instruction) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9643970B2 (en) * | 2011-10-10 | 2017-05-09 | H. Lundbeck A/S | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors |
| RS59534B1 (sr) | 2014-02-13 | 2019-12-31 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PH12020552066A1 (en) | 2014-02-13 | 2022-05-11 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| HRP20210543T1 (hr) | 2015-07-07 | 2021-05-14 | H. Lundbeck A/S | Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti |
| TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| MX389824B (es) | 2015-08-12 | 2025-03-20 | Incyte Holdings Corp | Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1). |
| CA3003549A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| IL262488B (en) | 2016-04-22 | 2022-08-01 | Incyte Corp | lsdi inhibitor formulations |
| CN109475556A (zh) * | 2016-07-06 | 2019-03-15 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| KR20190077349A (ko) * | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| SG11201903770UA (en) * | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| US20200157092A1 (en) * | 2017-02-27 | 2020-05-21 | Janssen Pharmaceutlca NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| IL270792B2 (en) | 2017-05-26 | 2024-01-01 | Imara Inc | Methods for the preparation and use of PDE9 inhibitors |
| TW201902898A (zh) | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
| WO2019101511A1 (en) | 2017-11-23 | 2019-05-31 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| EP3801526B1 (en) | 2018-05-25 | 2023-12-27 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one |
| AU2019289969A1 (en) * | 2018-06-20 | 2020-12-17 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| KR102831968B1 (ko) | 2018-08-31 | 2025-07-08 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN114302724A (zh) * | 2019-04-05 | 2022-04-08 | 伊马拉公司 | 用于治疗镰状细胞病的pde9抑制剂 |
| AU2020267475A1 (en) * | 2019-05-07 | 2021-12-23 | Imara Inc. | PDE9 inhibitors for treating thalassemia |
| WO2022036111A1 (en) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Methods and compositions for treating sickle cell disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1049695T3 (da) | 1997-11-12 | 2002-05-13 | Bayer Ag | 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer |
| WO2000043392A2 (de) * | 1999-01-20 | 2000-07-27 | Arzneimittelwerk Dresden Gmbh | Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| WO2003037432A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2005041972A1 (en) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2662594A1 (en) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Method and apparatus for producing a group iii nitride |
| AU2007332440B2 (en) | 2006-12-13 | 2013-05-16 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivative |
| EP2123301A4 (en) | 2006-12-13 | 2010-11-03 | Aska Pharm Co Ltd | Therapeutic agent for urinary tract disease |
| GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| TWI541244B (zh) * | 2010-09-20 | 2016-07-11 | 福倫製藥股份有限公司 | 咪唑三酮化合物 |
| SG11201400717QA (en) | 2011-10-07 | 2014-06-27 | Eisai R&D Man Co Ltd | Pyrazoloquinoline derivative |
| US9643970B2 (en) * | 2011-10-10 | 2017-05-09 | H. Lundbeck A/S | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors |
| HK1199879A1 (en) | 2012-01-26 | 2015-07-24 | H.隆德贝克有限公司 | Pde9 inhibitors with imidazo triazinone backbone |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
-
2012
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 CA CA2886885A patent/CA2886885C/en active Active
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/en active Active
- 2012-10-09 MX MX2019014982A patent/MX381326B/es unknown
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/en active Active
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 HK HK15111740.3A patent/HK1211023A1/xx unknown
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/en not_active Ceased
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN02829A (instruction) | ||
| PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
| PH12013500968A1 (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
| PH12012501202A1 (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a |